From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
about
Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International MeetingControlling dengue with vaccines in ThailandTackling dengue fever: Current status and challengesThe dengue vaccine pipeline: Implications for the future of dengue controlSafety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical TrialsPlant-produced candidate countermeasures against emerging and reemerging infections and bioterror agentsIntroducing a dengue vaccine to Mexico: development of a system for evidence-based public policy recommendationsAdvanced vaccine candidates for Lassa feverThe Complexity of a Dengue Vaccine: A Review of the Human Antibody ResponseMouse models to study dengue virus immunology and pathogenesisVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseLatest developments and future directions in dengue vaccinesDengue: an escalating public health problem in Latin AmericaImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesTrends in clinical trials of dengue vaccineVaccines and immunization strategies for dengue preventionIncomplete Protection against Dengue Virus Type 2 Re-infection in PeruDengue fever: a Wikipedia clinical reviewDengue research opportunities in the AmericasAdaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccinationMolecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidateHistorical Perspectives on Flavivirus ResearchLow levels of antibody-dependent enhancement in vitro using viruses and plasma from dengue patients.CD4+ and CD8+ T-cell immunity to Dengue - lessons for the study of Zika virus.T-cell immunity to infection with dengue virus in humans.Dengue epidemiological trend in Oman: a 13-year national surveillance and strategic proposition of imported cases.An overview of travel-associated central nervous system infectious diseases: risk assessment, general considerations and future directions.Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control.A DNA microarray-based assay to detect dual infection with two dengue virus serotypes.Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeysImmune correlates for dengue vaccine developmentThe re-emergence of dengue virus in non-endemic countries: a case series.Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccineDengue and other common causes of acute febrile illness in Asia: an active surveillance study in childrenDengue vaccines: recent developments, ongoing challenges and current candidates.Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in miceWill dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders.The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.
P2860
Q21562244-BF94C295-A026-48DC-B657-5FEA71777439Q21562250-ADFBED5A-BD70-4CA5-B610-FDED90BFAC12Q24288867-65B999D0-951C-4A69-9E76-1A2D65061C57Q26314683-82C6A3DE-9E74-4275-A948-499BB9271222Q26700096-8070F5F6-ED33-4110-9DDA-23C8FAB289E3Q26783107-C46D2458-F94F-43D8-9C9D-4F52020499AFQ26823330-7A4EBF45-D9B4-4853-A7E1-DAD4706B7CB6Q26823627-795CCE52-6DBC-4A59-BCA8-02A23B2EE2E3Q26995782-D6FF12BF-B5E0-4771-A66F-BC406E78FFD9Q27010151-16FA8996-B7FD-4BF4-81FC-A849B54FDCD7Q27014663-E116966F-885B-48E7-B784-4038ACE757CFQ27023422-817BAB17-7783-4904-AE06-EF9A948148C6Q27025794-31F0DB07-D926-4D2C-8E5E-BFCDF409A20EQ27319783-25BF91EA-F819-4EF8-9409-4A60AB6FFAC9Q28074355-857F4F78-FFE7-4FEA-BA94-CC7401ABFEEAQ28077521-D6B92E03-B5FE-4476-94BA-ED607002F387Q28550030-BB90D101-F361-4284-AB21-668D88DE4BEBQ28651505-904AE005-1F96-42CF-98A8-8336794EC830Q28656204-9644D656-1BFD-4161-AAB4-3CF2B193AEBAQ29274569-3C25E6A6-41F9-4C7C-B352-042D4A2F1A3CQ29587283-DC031863-C88C-450D-82C2-A3355A5E0C9BQ29994534-D859946D-B917-4B1C-97D3-C1D26A935F9EQ30392050-8F6142AC-077B-47DB-99C7-D3077CBC5C68Q30394327-4E95B683-F79D-40E4-9A00-894A9DFA93D9Q33414009-875AA926-F941-40C1-A1CE-4291DD3971DAQ33416278-398E9E81-EE82-40A3-9EA2-B213A7D03B78Q33682010-21A0AAD5-C3A3-46FA-8C48-0565BC002047Q33709817-7CA45342-1BDB-4B83-BAD4-E49D3A2DA4AEQ33775939-2E797F05-9179-4B72-BDCD-F803ACA6857CQ33800244-833E2E49-4F4D-4872-94D5-821A1EB781EAQ33924674-E0FDED53-A807-4B2C-879F-03AE1BD1DDAEQ34241685-1CE392E8-A531-45C0-8C6F-41B50C144513Q34262245-D47C311F-40EB-4B7A-8AA5-DCD2FE1C8204Q34363455-08A21B49-2107-4327-BF01-D5F7D081868AQ34367194-79AEDF57-97D7-4E87-B05A-E4968C0E2E11Q34607919-B3461302-62D4-402B-93AE-B4EFFA7F7EEFQ34614953-767646A3-2936-4ADA-8060-6CE4D3A30AEBQ34615061-EF6A5E48-C774-4B91-B53B-198D496C9293Q34630584-E32A2624-78E5-42D7-9190-6A9AC7729F8AQ34992520-D3B2E79F-5330-4746-BF69-F9B7A0E8A779
P2860
From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
From research to phase III: pr ...... eur tetravalent dengue vaccine
@ast
From research to phase III: pr ...... eur tetravalent dengue vaccine
@en
From research to phase III: pr ...... eur tetravalent dengue vaccine
@nl
type
label
From research to phase III: pr ...... eur tetravalent dengue vaccine
@ast
From research to phase III: pr ...... eur tetravalent dengue vaccine
@en
From research to phase III: pr ...... eur tetravalent dengue vaccine
@nl
prefLabel
From research to phase III: pr ...... eur tetravalent dengue vaccine
@ast
From research to phase III: pr ...... eur tetravalent dengue vaccine
@en
From research to phase III: pr ...... eur tetravalent dengue vaccine
@nl
P2093
P3181
P1433
P1476
From research to phase III: pr ...... eur tetravalent dengue vaccine
@en
P2093
Beatrice Barrere
Claire Malinowski
Melanie Saville
Remy Teyssou
P304
P3181
P356
10.1016/J.VACCINE.2011.06.094
P407
P5008
P577
2011-09-23T00:00:00Z